Oct. 19 at 10:55 PM
$CORT for both subgroups. Relacorilant plus nab-paclitaxel was well-tolerated in the PARPi
subgroups, consistent with its known safety profile. Importantly, the type, frequency and severity
of adverse events in the combination arms were comparable to those in the nab-paclitaxel
monotherapy arms. Relacorilant conferred its benefit without increasing the safety burden of the
patients who received it.
“These new ROSELLA data substantiate the significant benefit of relacorilant plus nab-paclitaxel
in platinum-resistant ovarian cancer, an extremely difficult-to-treat cancer,” said Domenica
Lorusso, M.D., Ph.D., Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio
X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano,
European Network of Gynaecological Oncological Trial groups Principal Investigator in the
ROSELLA trial and ESMO presenter. “These findings are especially promising for patients with an
exceptionally poor prognosis and
